NATCO Pharma Limited (BOM: 524816)
India
· Delayed Price · Currency is INR | Market Cap | 253.79B |
| Revenue (ttm) | 45.64B |
| Net Income (ttm) | 19.45B |
| Shares Out | n/a |
| EPS (ttm) | 108.58 |
| PE Ratio | 13.05 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Nov 27, 2024 |
| Volume | 30,228 |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | 783.60 - 1,638.35 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 11, 2025 |
About NATCO Pharma
NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosph... [Read more]
Financial Performance
In 2023, NATCO Pharma's revenue was 40.02 billion, an increase of 47.76% compared to the previous year's 27.09 billion. Earnings were 13.88 billion, an increase of 94.09%.
Financial StatementsNews
Natco Pharma reports 90.8% YoY export growth in November
Natco Pharma has delivered remarkable export growth for November 2024, marking a standout performance among API and formulation companies. The company recorded a significant 90.8% year-over-year (YoY)...
Natco Pharma shares rise after selling Telangana land for Rs 115.6 crore
Shares of Natco Pharma edged up 1.01% to ₹1,364.90 in early trading today, following the company’s announcement of selling a 14.38-acre land parcel in Telangana for ₹115.57 crore. The transaction incl...
Natco Pharma sells Telangana land for ₹115.57 crore
Natco Pharma Limited has announced the sale of a 14.38-acre land parcel, equivalent to 72,358 square yards, located at Mekaguda Gram Panchayat, Nandigama Mandal, Ranga Reddy District, Telangana.
Natco Pharma submits ANDA for Risdiplam for oral solution
Natco Pharma has announced its submission of an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification to the U.S. FDA for the generic version of EVRYSDI® (Risdiplam) 0.75 mg/mL Ora...
Natco Pharma Q2 FY24-25 Results: Revenue rises 32.1% YoY to ₹1,371 crore, profit surges 81.2% to ₹676.5 crore
Natco Pharma Limited has reported strong financial results for the second quarter ended September 30, 2024, showcasing significant growth in both revenue and profitability. Quarterly Financial Highlig...
Natco Pharma Q2 FY25 results: Stock surge over 2% ahead of result announcement
Shares of Natco Pharma saw a notable rise of over 2%, reaching an intraday high of ₹1,435.40, as investors eagerly anticipate the company’s upcoming Q2 FY25 results. The stock opened at ₹1,402.00 and ...
Q2 results today: Hyundai Motor India, Bosch, Zydus Lifesciences, Nykaa, Unno Minda, 3M India, Natco Pharma, TBO Tek among companies to announce earnings
A diverse group of companies, including Hyundai Motor India, Bosch, Zydus Lifesciences, and FSN E-Commerce Ventures (Nykaa), are set to announce their Q2 FY24-25 financial results today. Here’s a list...
Health groups join patent war over spinal muscular atrophy drug
Public health groups are challenging Roche's attempt to block a generic version of its expensive Spinal Muscular Atrophy drug, Risdiplam. They argue that Roche's patent infringement lawsuit against Na...